Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective,multi-centre,International Extranodal Lymphoma Study Group study |
| |
| Institution: | 1. Division Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Victoria, Australia;2. Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada;3. Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;4. Department of Statistics and Clinical Trials, Peter MacCallum Cancer Centre, East Melbourne, Australia;5. Department of Radiation Oncology, Brigham and Women''s Hospital, Boston, USA;6. Radiation Oncology Victoria, East Melbourne, Victoria, Australia;7. Department of Radiation Oncology, Stanford University, Stanford, USA;8. Hemato-oncology, Hopital Saint-Louis, Paris, France;9. Klinik für Radioonkologie und Strahlentherapie, Charité–Universitätsmedizin Berlin Campus Benjamin Franklin, Berlin, Germany;10. Department of Oncology and Haematology, The Finsen Centre, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark;11. Centrum Onkologii-Inst. Im. M. Sklodowskiej-Curie, Krakow, Poland;12. Freeman Hospital, High Heaton, Newcastle upon Tyne, UK;13. Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Victoria, Australia;14. Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland |
| |
| Abstract: | BackgroundWe evaluated the long-term results of radiotherapy for patients with gastric marginal zone lymphoma (GMZL).Patients and methodsWe carried out a retrospective, multi-centre study of patients with low-grade GMZL treated by radiotherapy between 17 July 1981 and 25 March 2004.ResultsThere were 102 eligible patients. Fifty-eight patients were previously untreated and 44 had recurrent/residual disease after prior treatment (HP eradication, chemotherapy and surgery in 35, 9 and 8 patients, respectively, and 7 had >1 prior therapy). Radiation fields included the stomach /involved nodes in 61 patients and whole abdomen in 41. The median radiotherapy dose to stomach was 40 Gy (range 26–46 Gy) in a median 22 fractions. With a median follow-up after radiotherapy of 7.9 years (range 0.3–24 years), 10- and 15-year freedom from treatment failure (FFTF) was 88% (95% CI 82%–95%). Risk factors for TF were a large-cell component (P = 0.036) and an exophytic growth pattern (P = 0.042). Radiotherapy field size, radiotherapy dose, and failure of prior therapy were not associated with inferior FFTF. Ten-year overall survival was 70% (95% CI 60%–82%).ConclusionsRadiotherapy achieves cure for the majority of patients with low-grade GMZL, including patients who have had prior therapy. Several features may predict a poorer outcome. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
